Mesothelioma Pipeline Insight 2025: Emerging Immunotherapies and Targeted Agents Aim to Redefine Outcomes in an Aggressive Cancer | DelveInsight

DelveInsight's "Mesothelioma - Pipeline Insight, 2025" report offers a detailed overview of the clinical and developmental pipeline for mesothelioma-an aggressive and rare cancer primarily linked to asbestos exposure, with poor prognosis and limited treatment options.

Despite decades of therapeutic stagnancy, 2025 marks a pivotal point in mesothelioma research, with a growing pipeline of novel agents targeting both tumor biology and the tumor microenvironment. Standard therapies such as chemotherapy and surgery have shown limited long-term survival benefits, prompting a strategic shift toward precision oncology and immunotherapy.

Several key companies are advancing innovative therapies. AstraZeneca is evaluating combinations involving immune checkpoint inhibitors (e.g., durvalumab and tremelimumab), while Sellas Life Sciences is developing galinpepimut-S, a WT1-targeting cancer vaccine. Additionally, Targovax, Atara Biotherapeutics, and TRACON Pharmaceuticals are progressing therapies involving oncolytic viruses, T-cell engagers, and anti-angiogenic agents, respectively, signaling diverse approaches being pursued in the clinical space.

The report includes in-depth profiles of late- and early-stage assets, trial design insights, MOAs, and upcoming regulatory milestones, providing strategic direction for stakeholders invested in mesothelioma drug development.

With momentum building around immunotherapy, epigenetic modulators, and tumor-specific vaccines, the mesothelioma pipeline is evolving rapidly, offering new hope for improved survival and quality of life in a historically underserved patient population.

Interested in learning more about the current treatment landscape and the key drivers shaping the mesothelioma pipeline? Click here: https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's mesothelioma pipeline analysis depicts a strong space with 45+ active players working to develop 50+ pipeline drugs for mesothelioma treatment.
• The leading mesothelioma companies include Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, Ascentage Pharma Group Inc., 7 Hills Pharma, LLC, and others are evaluating their lead assets to improve the mesothelioma treatment landscape.
• Key mesothelioma pipeline therapies in various stages of development include Pegargiminase, Volrustomig, Tremelimumab, TAK-500, RSO-021, VT3989, VMD-928, VET3-TG, UCMYM802 Injection, TNG908, SynKIR-110, SW-682, Sacituzumab, NX-1607, MesoPher, Lenvatinib, CPI-0209, BGC515, AROG4-01, APG-2449, Alintegimod, and others.
• In June 2025, Oncovita announced that the FDA granted Orphan Drug Designation to its lead investigational therapy, MVdeltaC, for the treatment of pleural mesothelioma, a rare and aggressive cancer with limited treatment options.
• In September 2024, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for patients with unresectable advanced or metastatic malignant pleural mesothelioma.

Request a sample and discover the recent breakthroughs happening in the mesothelioma pipeline landscape at https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Mesothelioma Overview
Mesothelioma is a rare, aggressive cancer most commonly caused by exposure to asbestos, particularly the amosite and crocidolite types. It typically affects the pleura (the lining of the lungs), but can also occur in the peritoneum or pericardium. The disease has a long latency period and is most often seen in individuals with occupational asbestos exposure, especially in industries such as shipbuilding. While stricter regulations have led to a decline in incidence, mesothelioma remains a concern in regions with historical asbestos use. It is more frequently diagnosed in men, and most cases are identified at an advanced stage, making treatment more challenging.

Find out more about mesothelioma medication at https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Mesothelioma Treatment Analysis: Drug Profile
Pegargiminase (ADI‐PEG 20): Polaris Pharmaceuticals
Pegargiminase is a biologic therapy in late-stage development, targeting various cancers with specific metabolic vulnerabilities. It works by depleting arginine-an amino acid critical for tumor growth-by converting it into citrulline. This is particularly effective in cancers deficient in argininosuccinate synthase (ASS1), an enzyme required to synthesize arginine. The resulting metabolic stress sensitizes tumor cells to conventional chemotherapy. Pegargiminase has received Orphan Drug Designation for mesothelioma in both the U.S. and Europe and is currently in the preregistration phase for mesothelioma treatment.

Volrustomig: AstraZeneca
Volrustomig is a bispecific monoclonal antibody engineered to simultaneously target PD-1 and CTLA-4, two immune checkpoint proteins that suppress T-cell activity. By blocking both pathways, Volrustomig enhances immune responses against tumors. It is currently in Phase III clinical development for mesothelioma and aims to improve outcomes by reactivating tumor-infiltrating lymphocytes (TILs) and promoting a stronger anti-cancer immune attack.

Tremelimumab: MedImmune LLC
Tremelimumab is a fully human monoclonal antibody that blocks CTLA-4, a protein that downregulates T-cell activation. By inhibiting CTLA-4, tremelimumab enhances the immune system's ability to recognize and destroy cancer cells. It has been granted both Orphan Drug and Fast Track Designations by the FDA and is currently undergoing Phase II clinical trials for the treatment of mesothelioma.

Learn more about the novel and emerging mesothelioma pipeline therapies at https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Mesothelioma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Mesothelioma Pipeline Report
• Coverage: Global
• Key Mesothelioma Companies: Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, Ascentage Pharma Group Inc., 7 Hills Pharma, LLC, and others.
• Key Mesothelioma Pipeline Therapies: Pegargiminase, Volrustomig, Tremelimumab, TAK-500, RSO-021, VT3989, VMD-928, VET3-TG, UCMYM802 Injection, TNG908, SynKIR-110, SW-682, Sacituzumab, NX-1607, MesoPher, Lenvatinib, CPI-0209, BGC515, AROG4-01, APG-2449, Alintegimod, and others.

To dive deep into rich insights for drugs used for mesothelioma treatment, visit: https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Mesothelioma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Mesothelioma Pipeline Therapeutics
6. Mesothelioma Pipeline: Late-Stage Products (Phase III)
7. Mesothelioma Pipeline: Mid-Stage Products (Phase II)
8. Mesothelioma Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.